Climb Bio (CLYM) Stock Price, News & Analysis

Company Overview

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Key Stats

• Today's Range: $1.25 to $1.33
• 50-Day Range: $1.13 to $1.48
• 52-Week Range: $1.05 to $10.86
• Volume: 124,938 shs
• Average Volume: 303,223 shs
• Market Capitalization: $84.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Strong Buy

CLYM Stock Analysis - Frequently Asked Questions

How have CLYM shares performed this year?

Climb Bio's stock was trading at $1.80 at the beginning of 2025. Since then, CLYM stock has decreased by 30.6% and is now trading at $1.25.
View the best growth stocks for 2025 here.

How were Climb Bio's earnings last quarter?

Climb Bio, Inc. (NASDAQ:CLYM) issued its earnings results on Tuesday, March, 25th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02.

Who are Climb Bio's major shareholders?

Climb Bio's top institutional investors include Peapod Lane Capital LLC (0.82%) and Bank of New York Mellon Corp (0.10%).
View institutional ownership trends.

How do I buy shares of Climb Bio?

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/25/2025
• Today: 5/05/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLYM
• Previous Symbol: NASDAQ:CLYM
• CIK: 1768446
• Web: climbbio.com
• Phone: 866-857-2596
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +663.4%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.21%
• Return on Assets: -41.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 57.73
• Quick Ratio: 57.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.90 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 67,576,000
• Free Float: 65,073,000
• Market Cap: $88.52 million
• Optionable: N/A
• Beta: -0.12